Search

Your search keyword '"Velásquez, Gustavo E."' showing total 26 results
Start Over Author "Velásquez, Gustavo E." Search Limiters Full Text
26 results on '"Velásquez, Gustavo E."'

2. Outcomes of a Career Development Program for Underrepresented Minority Investigators in the AIDS Clinical Trials Group

Author

Velásquez, Gustavo E, Huaman, Moises A, Powell, Kimberly R, Cohn, Susan E, Swaminathan, Shobha, Outlaw, Martine, Schulte, Gail, McNeil, Quinteka, Currier, Judith S, Del Rio, Carlos, and Castillo-Mancilla, Jose

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Prevention, Clinical Research, HIV/AIDS, Genetics, Infectious Diseases, Infection, Good Health and Well Being, career development, infectious diseases, mentorship, minority investigators, training, Clinical sciences, Medical microbiology
Abstract

We surveyed awardees of the Minority HIV Investigator Mentoring Program (MHIMP) of the AIDS Clinical Trials Group. Most reported clinical specialization in infectious diseases or HIV medicine (86%), and all but 1 (95%) are engaged in medical/health sciences research. The MHIMP helped retain early-career minority investigators in HIV/AIDS-related research.

Published
2019

4. Experience With Four-Month Rifapentine and Moxifloxacin–Based Tuberculosis Treatment in San Francisco.

Author

Louie, Janice K, Agraz-Lara, Rocio, Velásquez, Gustavo E, Phillips, Allison, and Szumowski, John D

Subjects
TUBERCULOSIS, RANDOMIZED controlled trials, TREATMENT effectiveness
Abstract

Background A multicountry randomized controlled trial has demonstrated that pan-susceptible pulmonary tuberculosis (TB) can be successfully treated with a 4-month regimen of daily isoniazid, rifapentine, moxifloxacin, and pyrazinamide (HPMZ). We piloted HPMZ in San Francisco (SF) using a modified version of the US Centers for Disease Control and Prevention HPMZ treatment guidelines. Methods In this retrospective cohort, patients consecutively referred to SF TB clinic were evaluated for HPMZ eligibility based on preestablished inclusion/exclusion criteria. All underwent evaluation and management according to national recommendations. We reviewed the medical records of those initiated on HPMZ. Results From August 2021 to December 2023, 30 (18.8%) of 160 patients diagnosed with active TB met HPMZ inclusion criteria; of these, 22 (13.8%) started HPMZ. The median age (range) was 32.5 (14–86) years, 17 (77.3%) were otherwise healthy, and 19 (86.4%) had pulmonary TB, including 7 (36.8%) with cavitary disease. Eighteen (81.8%) patients had an adverse event, with 11 (50%) prematurely discontinuing HPMZ; the most common adverse events were vomiting, elevated transaminases, and rash. To date, 9 (40.9%) have completed treatment, with most achieving criteria for cure. One patient was diagnosed with possible TB recurrence and restarted standard TB treatment. Conclusions Our experience, with half of patients to date prematurely discontinuing HPMZ, illustrates the challenge of extrapolating findings from TB clinical trials commonly conducted in high-incidence, non-US settings to US clinical practice. Further experience may help identify best practices for implementing HPMZ, including identifying predictors of which patients may be most likely to benefit from and tolerate this regimen. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Recent advances in the treatment of tuberculosis

Author

Motta, Ilaria, primary, Boeree, Martin, additional, Chesov, Dumitru, additional, Dheda, Keertan, additional, Günther, Gunar, additional, Horsburgh JR, C. Robert, additional, Kherabi, Yousra, additional, Lange, Christoph, additional, Lienhardt, Christian, additional, McIlleron, Helen M., additional, Paton, Nicholas I., additional, Stagg, Helen R., additional, Thwaites, Guy, additional, Udwadia, Zarir, additional, Van Crevel, Reinout, additional, Velásquez, Gustavo E., additional, Wilkinson, Robert J., additional, and Guglielmetti, Lorenzo, additional

Published
2023
Full Text
View/download PDF

6. Respiratory, Cardiac, and Neuropsychiatric Manifestations of Postacute Sequelae of Coronavirus Disease 2019 in Lima, Peru

Author

Rahman, Rifat S, primary, Tovar, Marco A, additional, Peinado, Jesús, additional, Palomino, J Santiago, additional, Ramirez, Claudio, additional, Llanos-Zavalaga, Fernando, additional, Peralta, Ernesto, additional, Valderrama, Gissela, additional, Ramos Cordova, Lourdes B, additional, Sanchez Cortez, Lucero I, additional, Rodriguez, German, additional, LaHood, Allison N, additional, Franke, Molly F, additional, Mitnick, Carole D, additional, Lecca, Leonid, additional, and Velásquez, Gustavo E, additional

Published
2023
Full Text
View/download PDF

8. Additional file 1 of Low detection rate of RT-PCR-confirmed COVID-19 using IgM/IgG rapid antibody tests in a large community sample in Lima, Peru

Author

Law, Stephanie, Tovar, Marco A., Franke, Molly F., Calderon, Roger, Palomino, Santiago, Valderrama, Gissella, Llanos, Fernando, Velásquez, Gustavo E., Mitnick, Carole D., and Lecca, Leonid

Abstract

Additional file 1. Table S1. Reported symptoms of all participants with sample collected (and tested) for serologic antibody test on same day as sample that resulted in RT-PCR positive for SARS-CoV-2 (n=492); no symptom duration outliers excluded. Table S2. Reported symptoms of all participants with sample collected (and tested) for serologic antibody test on same day as sample that resulted in RT-PCR positive for SARS-CoV-2 (n=492); mild and extreme symptom duration outliers excluded. Table S3. Sensitivity of the rapid antibody test# by symptom duration and outlier exclusion criteria. Fig. S1. Plots of antibody test sensitivity against the number of weeks since onset of symptoms among those who reported at least one symptom before testing, using the RT-PCR test as the reference, stratified by the types of outliers excluded in the analysis: extreme outliers, which were defined as persons whose time since symptom onset was longer than the third quartile plus 3 times the interquartile range (IQR, defined as the difference between the first and third quartile of the reported times since onset for a given symptom); mild outliers were those beyond the third quartile plus 1.5 times the IQR); or no outliers excluded. The circles show the crude estimated sensitivity and the error bars show the Wilson’s score 95% confidence intervals. The plotted lines are the fitted segmented linear regressions for the rapid antibody tests. Table S4. Segmented regression analyses of antibody test sensitivity by weeks since symptom onset, by symptom duration outlier exclusion criteria. Table S5. Overall antibody test sensitivity* per week since symptom onset for common symptoms. Table S6.Segmented regression analyses of antibody test sensitivity versus weeks since symptom onset, by symptom.

Published
2023
Full Text
View/download PDF

10. Diagnostic Performance Assessment of Saliva RT-PCR and Nasopharyngeal Antigen for the Detection of SARS-CoV-2 in Peru

Author

Calderón, Roger I., primary, Jhaveri, Tulip A., additional, Tovar, Marco A., additional, Palomino, J. Santiago, additional, Barreda, Nadia N., additional, Sanabria, Oswaldo M., additional, Peinado, Jesús, additional, Ramirez, Claudio, additional, Llanos Zavalaga, L. Fernando, additional, Valderrama, Gissela, additional, Franke, Molly F., additional, Mitnick, Carole D., additional, Lecca, Leonid, additional, and Velásquez, Gustavo E., additional

Published
2022
Full Text
View/download PDF

15. Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis

Author

Velásquez, Gustavo E., primary, Brooks, Meredith B., additional, Coit, Julia M., additional, Sánchez Garavito, Epifanio, additional, Calderón, Roger I., additional, Jiménez, Judith, additional, Tintaya, Karen, additional, Peloquin, Charles A., additional, Osso, Elna, additional, Lecca, Leonid, additional, Davies, Geraint R., additional, and Mitnick, Carole D., additional

Published
2019
Full Text
View/download PDF

16. Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial

Author

Velásquez, Gustavo E., primary, Brooks, Meredith B., additional, Coit, Julia M., additional, Pertinez, Henry, additional, Vargas Vásquez, Dante, additional, Sánchez Garavito, Epifanio, additional, Calderón, Roger I., additional, Jiménez, Judith, additional, Tintaya, Karen, additional, Peloquin, Charles A., additional, Osso, Elna, additional, Tierney, Dylan B., additional, Seung, Kwonjune J., additional, Lecca, Leonid, additional, Davies, Geraint R., additional, and Mitnick, Carole D., additional

Published
2018
Full Text
View/download PDF

18. Erratum for Velásquez et al., Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis

Author

Velásquez, Gustavo E., primary, Calderon, Roger I., additional, Mitnick, Carole D., additional, Becerra, Mercedes C., additional, Huang, Chuan-Chin, additional, Zhang, Zibiao, additional, Contreras, Carmen C., additional, Yataco, Rosa M., additional, Galea, Jerome T., additional, Lecca, Leonid W., additional, and Murray, Megan B., additional

Published
2017
Full Text
View/download PDF

19. Nutritional Status and Tuberculosis Risk in Adult and Pediatric Household Contacts

Author

Aibana, Omowunmi, primary, Acharya, Xeno, additional, Huang, Chuan-Chin, additional, Becerra, Mercedes C., additional, Galea, Jerome T., additional, Chiang, Silvia S., additional, Contreras, Carmen, additional, Calderon, Roger, additional, Yataco, Rosa, additional, Velásquez, Gustavo E., additional, Tintaya, Karen, additional, Jimenez, Judith, additional, Lecca, Leonid, additional, and Murray, Megan B., additional

Published
2016
Full Text
View/download PDF

20. Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis

Author

Velásquez, Gustavo E., primary, Calderon, Roger I., additional, Mitnick, Carole D., additional, Becerra, Mercedes C., additional, Huang, Chuan-Chin, additional, Zhang, Zibiao, additional, Contreras, Carmen C., additional, Yataco, Rosa M., additional, Galea, Jerome T., additional, Lecca, Leonid W., additional, and Murray, Megan B., additional

Published
2016
Full Text
View/download PDF

22. Impact of HIV on mortality among patients treated for tuberculosis in Lima, Peru: a prospective cohort study

Author

Velásquez, Gustavo E., primary, Cegielski, J. Peter, additional, Murray, Megan B., additional, Yagui, Martin J. A., additional, Asencios, Luis L., additional, Bayona, Jaime N., additional, Bonilla, César A., additional, Jave, Hector O., additional, Yale, Gloria, additional, Suárez, Carmen Z., additional, Sanchez, Eduardo, additional, Rojas, Christian, additional, Atwood, Sidney S., additional, Contreras, Carmen C., additional, Cruz, Janeth Santa, additional, and Shin, Sonya S., additional

Published
2015
Full Text
View/download PDF

24. Impact of HIV on mortality among patients treated for tuberculosis in Lima, Peru: a prospective cohort study.

Author

Velásquez, Gustavo E., Cegielski, J. Peter, Murray, Megan B., Yagui, Martin J. A., Asencios, Luis L., Bayona, Jaime N., Bonilla, César A., Jave, Hector O., Yale, Gloria, Suárez, Carmen Z., Sanchez, Eduardo, Rojas, Christian, Atwood, Sidney S., Contreras, Carmen C., Cruz, Janeth Santa, Shin, Sonya S., and Santa Cruz, Janeth

Subjects
*HIV infections, *THERAPEUTICS, *TUBERCULOSIS, *LONGITUDINAL method, *HEALTH outcome assessment, *SPUTUM, *TUBERCULOSIS mortality, *HIV infection complications, *TUBERCULOSIS epidemiology, *HIV infection epidemiology, *MULTIVARIATE analysis, *RESEARCH funding, *DISEASE prevalence, *PROPORTIONAL hazards models
Abstract

Background: Human immunodeficiency virus (HIV)-associated tuberculosis deaths have decreased worldwide over the past decade. We sought to evaluate the effect of HIV status on tuberculosis mortality among patients undergoing treatment for tuberculosis in Lima, Peru, a low HIV prevalence setting.Methods: We conducted a prospective cohort study of patients treated for tuberculosis between 2005 and 2008 in two adjacent health regions in Lima, Peru (Lima Ciudad and Lima Este). We constructed a multivariate Cox proportional hazards model to evaluate the effect of HIV status on mortality during tuberculosis treatment.Results: Of 1701 participants treated for tuberculosis, 136 (8.0%) died during tuberculosis treatment. HIV-positive patients constituted 11.0% of the cohort and contributed to 34.6% of all deaths. HIV-positive patients were significantly more likely to die (25.1 vs. 5.9%, P < 0.001) and less likely to be cured (28.3 vs. 39.4%, P = 0.003). On multivariate analysis, positive HIV status (hazard ratio [HR] = 6.06; 95% confidence interval [CI], 3.96-9.27), unemployment (HR = 2.24; 95% CI, 1.55-3.25), and sputum acid-fast bacilli smear positivity (HR = 1.91; 95% CI, 1.10-3.31) were significantly associated with a higher hazard of death.Conclusions: We demonstrate that positive HIV status was a strong predictor of mortality among patients treated for tuberculosis in the early years after Peru started providing free antiretroviral therapy. As HIV diagnosis and antiretroviral therapy provision are more widely implemented for tuberculosis patients in Peru, future operational research should document the changing profile of HIV-associated tuberculosis mortality. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

25. Targeted Drug-Resistance Testing Strategy for Multidrug-Resistant Tuberculosis Detection, Lima, Peru, 2005–2008

Author

Velásquez, Gustavo E., primary, Yagui, Martin, additional, Cegielski, J. Peter, additional, Asencios, Luis, additional, Bayona, Jaime, additional, Bonilla, Cesar, additional, Jave, Hector O., additional, Yale, Gloria, additional, Suárez, Carmen, additional, Atwood, Sidney, additional, Contreras, Carmen C., additional, and Shin, Sonya S., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results